In the original article, all references for in [Tables 1](#T1){ref-type="table"}, [2](#T2){ref-type="table"} were incorrectly listed. The corrected references for both [Table 1](#T1){ref-type="table"} and [Table 2](#T2){ref-type="table"} have been corrected and provided below.

###### 

Metabolic dependencies in PDA.

  **Event**                             **Mediated by**           **References**
  ------------------------------------- ------------------------- ------------------
  **MITOCHONDRIAL METABOLISM**                                    
  Increased oxidative phosphorylation   Down regulation of Drp1   ([@B61])
                                        HuR                       ([@B50])
  Increased biogenesis                  HuR                       Unpublished
  **NUTRIENT ACQUISITION**                                        
  Autophagy                             Oncogenic KRAS            ([@B74])
  NAD^+^ salvage pathway                miR-206                   ([@B78], [@B79])
  Macropinocytosis                      Oncogenic KRAS            ([@B35])
  Increased alanine uptake              Oncogenic KRAS            ([@B85])
  **REDOX HOMEOSTASIS**                                           
  Upregulation of ME1                   Oncogenic KRAS            ([@B57])
  Upregulation of NRF2                  Oncogenic KRAS            ([@B97])
  Upregulation of IDH1                  HuR                       ([@B50])

###### 

Clinical trials targeting key steps of PDA metabolism.

  **Target**                 **Agent**                                **Phase and status**   **NCT No**.   **References**
  -------------------------- ---------------------------------------- ---------------------- ------------- --------------------
  **MITOCHONDRIAL OXPHOS**                                                                                 
  ETC                        Metformin + gemcitabine + ertotinib      II; Completed          NCT01210911   ([@B63])
                             Metformin + paclitaxel                   II; Completed          NCT01971034   ([@B103])
                             Metformin + gemcitabine/nab-paclitaxel   I; Recruiting          NCT02336087   
                             Metformin + mFOLFIRINOX                  II; Active             NCT01666730   
                             Metformin + rapamycin                    Ib; Active             NCT02048384   
                             Metformin + radiosurgery                 I; Active              NCT02153450   
  TCA cycle                  CPI-613                                  I; Completed           NCT01839981   
                             CPI-613 + mFOLFIRINOX                    I; Active              NCT01835041   ([@B67])
                             CPI-613 + gemcitabine/nab-paclitaxel     I; Active              NCT03435289   
  **NUTRIENT ACQUISITION**                                                                                 
  Autophagy                  HCQ                                      II; Completed          NCT01273805   ([@B104])
                             HCQ + gemcitabine                        I/II; Active           NCT01128296   
                             HCQ + gemcitabine + abraxane             I/II; Active           NCT01506973   
                             CQ + gemcitabine                         I; Completed           NCT01777477   ([@B105], [@B106])
  **REDOX HOMEOSTASIS**                                                                                    
  Glutaminase                CB-839                                   I; Active              NCT02071862   

*HCQ, hydroxychloroquine; CQ, chloroquine; mFOLFIRINOX, modified FOLFIRINOX*.

In the original article, references in [Table 2](#T2){ref-type="table"} were not provided in the reference list. The references have now been inserted.

The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.
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